Terms: = Colorectal cancer AND PIM1, PIM, 5292, ENSG00000137193, P11309 AND Treatment
19 results:
1. KZ02 enhances the radiosensitivity of BRAF-mutated CRC in vitro and in vivo.
Guo Y; Li X; Yuan R; Ren J; Huang Y; Yu Y; Tian H
Eur J Pharmacol; 2023 Nov; 959():176060. PubMed ID: 37775019
[TBL] [Abstract] [Full Text] [Related]
2. Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective pim1 inhibitor in human colon cancer.
Park YS; Kim J; Ryu YS; Moon JH; Shin YJ; Kim JH; Hong SW; Jung SA; Lee S; Kim SM; Lee DH; Kim DY; Yun H; You JE; Yoon DI; Kim CH; Koh DI; Jin DH
Cancer Biol Ther; 2023 Dec; 24(1):2246208. PubMed ID: 37621144
[TBL] [Abstract] [Full Text] [Related]
3. Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and pim-1 kinase enzymes.
El-Miligy MMM; Al-Kubeisi AK; El-Zemity SR; Nassra RA; Abu-Serie MM; Hazzaa AA
Bioorg Chem; 2021 Oct; 115():105171. PubMed ID: 34303896
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic and immunomodulatory effects of pim1 in colorectal carcinoma.
Zhou Y; Zhou Y; Liu S; Wang J; Ji R; Yan X
J BUON; 2021; 26(2):513-520. PubMed ID: 34077000
[TBL] [Abstract] [Full Text] [Related]
5. Effects of pim3 in prognosis of colon cancer.
Zhou Y; Zhou YN; Liu SX; Wang J; Ji R; Yan X
Clin Transl Oncol; 2021 Oct; 23(10):2163-2170. PubMed ID: 33928496
[TBL] [Abstract] [Full Text] [Related]
6. Long-term anorectal function in rectal cancer patients treated with chemoradiotherapy and endorectal brachytherapy.
Faaborg PM; Haas S; Liao D; Ploen J; Jakobsen A; Rahr HB; Laurberg S; Gregersen H; Lundby L; Christensen P; Krogh K
Colorectal Dis; 2021 Sep; 23(9):2311-2319. PubMed ID: 33900676
[TBL] [Abstract] [Full Text] [Related]
7. PAI1 is a Marker of Bad Prognosis in Rectal cancer but Predicts a Better Response to treatment with pim Inhibitor AZD1208.
Muñoz-Galván S; Rivero M; Peinado-Serrano J; Martinez-Pérez J; Fernández-Fernández MC; Ortiz MJ; García-Heredia JM; Carnero A
Cells; 2020 Apr; 9(5):. PubMed ID: 32344898
[TBL] [Abstract] [Full Text] [Related]
8. Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with cancer Receiving First-Line Palliative Chemotherapy.
Hong S; Lee JH; Chun EK; Kim KI; Kim JW; Kim SH; Lee YG; Hwang IG; Kim JY; Koh SJ; Ko YH; Shin SH; Woo IS; Kim TY; Baek JY; Kim HJ; Kim HJ; Lee MA; Kwon JH; Hong YS; Ryoo HM; Kim JH
Oncologist; 2020 Mar; 25(3):e502-e511. PubMed ID: 32162799
[TBL] [Abstract] [Full Text] [Related]
9. Prevalence and factors associated with potentially inappropriate medication use in older medicare beneficiaries with cancer.
Feng X; Higa GM; Safarudin F; Sambamoorthi U; Chang J
Res Social Adm Pharm; 2020 Oct; 16(10):1459-1471. PubMed ID: 31926877
[TBL] [Abstract] [Full Text] [Related]
10. Potentially inappropriate medication use and associated healthcare utilization and costs among older adults with colorectal, breast, and prostate cancers.
Feng X; Higa GM; Safarudin F; Sambamoorthi U; Tan X
J Geriatr Oncol; 2019 Sep; 10(5):698-704. PubMed ID: 30772191
[TBL] [Abstract] [Full Text] [Related]
11. Hispidulin suppresses cell growth and metastasis by targeting pim1 through JAK2/STAT3 signaling in colorectal cancer.
Liu K; Gao H; Wang Q; Wang L; Zhang B; Han Z; Chen X; Han M; Gao M
Cancer Sci; 2018 May; 109(5):1369-1381. PubMed ID: 29575334
[TBL] [Abstract] [Full Text] [Related]
12. pim-3 as a potential predictor of chemoradiotherapy resistance in locally advanced rectal cancer patients.
Zhang RX; Zhou ZG; Lu SX; Lu ZH; Wan DS; Pan ZZ; Wu XJ; Chen G
Sci Rep; 2017 Nov; 7(1):16043. PubMed ID: 29167471
[TBL] [Abstract] [Full Text] [Related]
13. Hypoxia-Inducible pim Kinase Expression Promotes Resistance to Antiangiogenic Agents.
Casillas AL; Toth RK; Sainz AG; Singh N; Desai AA; Kraft AS; Warfel NA
Clin Cancer Res; 2018 Jan; 24(1):169-180. PubMed ID: 29084916
[No Abstract] [Full Text] [Related]
14. Potential Medication-Related Problems in Older Breast, Colon, and Lung cancer Patients in the United States.
Lund JL; Sanoff HK; Peacock Hinton S; Muss HB; Pate V; Stürmer T
Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):41-49. PubMed ID: 28978563
[No Abstract] [Full Text] [Related]
15. pim1 kinase phosphorylates the human transcription factor FOXP3 at serine 422 to negatively regulate its activity under inflammation.
Li Z; Lin F; Zhuo C; Deng G; Chen Z; Yin S; Gao Z; Piccioni M; Tsun A; Cai S; Zheng SG; Zhang Y; Li B
J Biol Chem; 2014 Sep; 289(39):26872-26881. PubMed ID: 25096571
[TBL] [Abstract] [Full Text] [Related]
16. Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma.
Weirauch U; Beckmann N; Thomas M; Grünweller A; Huber K; Bracher F; Hartmann RK; Aigner A
Neoplasia; 2013 Jul; 15(7):783-94. PubMed ID: 23814490
[TBL] [Abstract] [Full Text] [Related]
17. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma.
Ibrahim AF; Weirauch U; Thomas M; Grünweller A; Hartmann RK; Aigner A
Cancer Res; 2011 Aug; 71(15):5214-24. PubMed ID: 21690566
[TBL] [Abstract] [Full Text] [Related]
18. pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
Kim J; Roh M; Abdulkadir SA
BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
[TBL] [Abstract] [Full Text] [Related]
19. Identification of stemonamide synthetic intermediates as a novel potent anticancer drug with an apoptosis-inducing ability.
Li YY; Wang YY; Taniguchi T; Kawakami T; Baba T; Ishibashi H; Mukaida N
Int J Cancer; 2010 Jul; 127(2):474-84. PubMed ID: 19921695
[TBL] [Abstract] [Full Text] [Related]
